Status vedrørende Novo Nordisks beholdning af egne aktier

April 03, 2003 05:00 ET | Source: Novo Nordisk A/S Novo Nordisk A/S

Der er i første kvartal 2003 erhvervet i alt 2.975.000 stk. B-aktier, og der blev udnyttet i alt 3.000 optioner, der dækkes af Novo Nordisks beholdning af egne aktier.

Denne meddelelse fremsendes i henhold til New York Stock Exchange Listed Company Manual, afsnit 204.33, Treasury Stock Changes.

For yderligere information kontakt:

Medier:	Investorer:

Elin K. Hansen	Peter Haahr
Tlf. (direkte): 4442 3450	Tlf. (direkte): 4442 1207

	Palle Holm Olesen
	Tlf. (direkte): 4442 6175

	Christian Kanstrup
	Tlf. (direkte): 4443 7801

Fondsbørsmeddelelse nr. 8 / 2003

Attachments

Læs i PDF Format...

Recommended Reading

September 18, 2026 06:36 ET | Source: Novo Nordisk A/S

Novo’s once-weekly Sogroya® (somapacitan) receives positive CHMP opinion in Europe for children with idiopathic short stature (unexplained shortness)

Novo Nordisk receives positive opinion from the CHMP of the EMA, recommending once-weekly Sogroya® for children with idiopathic short stature
Read More
September 17, 2026 10:14 ET | Source: Novo Nordisk A/S

Novo: CHMP recommends EU approval of FREHEMGO® (denecimig), the first factor VIIIa mimetic offering monthly, once every two weeks and weekly dosing in a pre-filled pen, for the treatment of haemophilia A

EMA has adopted a positive opinion recommending marketing authorisation for FREHEMGO® (denecimig) to treat haemophilia A (HA), with or without inhibitors
Read More